Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

PerkinElmer Buys Haoyuan Biotech, a Diagnostics Company, for $38 Million

publication date: Nov 13, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
PerkinElmer paid $38 million to buy Shanghai Haoyuan Biotech Co., a company that has developed four SFDA-approved infectious disease diagnostic tests. The owners of Haoyuan may also receive future payments based on revenues hitting targets. The four assays, which test for hepatitis B, hepatitis C and HIV, are intended for use by blood banks and clinical labs. More details....

Stock Symbol: (NYSE: PKI)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors